Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation

Transplant Infectious Disease

Volumn 15, Issue 5, 2013, Pages 457-465

  Kawamura, K ^a   Wada, H ^a   Yamasaki, R ^a   Ishihara, Y ^a   Sakamoto, K ^a   Ashizawa, M ^a   Sato, M ^a   Machishima, T ^a   Terasako, K ^a   Kimura, S I ^a   Kikuchi, M ^a   Nakasone, H ^a   Yamazaki, R ^a   Kanda, J ^a   Kako, S ^a   Tanihara, A ^a   Nishida, J ^a   Kanda, Y ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

Acyclovir; Allogeneic hematopoietic stem cell transplantation; Herpes simplex virus disease

Indexed keywords

ACICLOVIR; HLA ANTIGEN; METHOTREXATE; VALACICLOVIR; ANTIVIRUS AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; DRUG TOLERABILITY; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX; HUMAN; LIP; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; PROPHYLAXIS; STOMATITIS; T CELL LEUKEMIA; TONGUE; VESICULAR RASH; ADVERSE EFFECTS; ALLOTRANSPLANTATION; DRUG EFFECTS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INCIDENCE; JAPAN; MIDDLE AGED; RETROSPECTIVE STUDY; SIMPLEXVIRUS; VIRUS ACTIVATION; YOUNG ADULT;

ACYCLOVIR; ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMPLEXVIRUS; TRANSPLANTATION, HOMOLOGOUS; VIRUS ACTIVATION; YOUNG ADULT;

EID: 84884977721     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12118     Document Type: Article

References (25)

1. Meyers JD, Flournoy N, Thomas ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980; 142 (3): 338-346.
2. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS. Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 1981; 305 (2): 63-67.
3. Gluckman E, Lotsberg J, Devergie A, et al. Prophylaxis of herpes infections after bone-marrow transplantation by oral acyclovir. Lancet 1983; 2 (8352): 706-708.
4. Hann IM, Prentice HG, Blacklock HA, et al. Acyclovir prophylaxis against herpes virus infections in severely immunocompromised patients: randomised double blind trial. Br Med J (Clin Res Ed) 1983; 287 (6389): 384-388.
5. Wade JC, Newton B, Flournoy N, Meyers JD. Oral acyclovir for prevention of herpes simplex virus reactivation after marrow transplantation. Ann Intern Med 1984; 100 (6): 823-828.
6. Shepp DH, Dandliker PS, Flournoy N, Meyers JD. Once-daily intravenous acyclovir for prophylaxis of herpes simplex virus reactivation after marrow transplantation. J Antimicrob Chemother 1985; 16 (3): 389-395.
7. Engelhard D, Morag A, Or R, et al. Prevention of herpes simplex virus (HSV) infection in recipients of HLA-matched T-lymphocyte-depleted bone marrow allografts. Isr J Med Sci 1988; 24 (3): 145-150.
8. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 (RR-10): 1-25, CE121-127.
9. Asano-Mori Y, Kanda Y, Oshima K, et al. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Am J Hematol 2008; 83 (6): 472-476.
10. Ashizawa M, Oshima K, Wada H, et al. Hyperbilirubinemia in the early phase after allogeneic HSCT: prognostic significance of the alkaline phosphatase/total bilirubin ratio. Bone Marrow Transplant 2013; 48 (1): 94-98.
11. Przepiorka D, Weisdorf D, Martin P, et al. 1994 consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15 (6): 825-828.
12. Kanda Y, Mineishi S, Saito T, et al. Response-oriented preemptive therapy against cytomegalovirus disease with low-dose ganciclovir: a prospective evaluation. Transplantation 2002; 73 (4): 568-572.
13. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6 (10): 1562-1568.
14. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18 (6): 695-706.
15. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999; 94 (446): 496-509.
16. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 2013; 48 (3): 452-458.
17. Shepp DH, Dandliker PS, Flournoy N, Meyers JD. Sequential intravenous and twice-daily oral acyclovir for extended prophylaxis of herpes simplex virus infection in marrow transplant patients. Transplantation 1987; 43 (5): 654-658.
18. Ljungman P, Wilczek H, Gahrton G, et al. Long-term acyclovir prophylaxis in bone marrow transplant recipients and lymphocyte proliferation responses to herpes virus antigens in vitro. Bone Marrow Transplant 1986; 1 (2): 185-192.
19. Kanda Y, Mineishi S, Saito T, et al. Long-term low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001; 28 (7): 689-692.
20. Wagstaff AJ, Faulds D, Goa KL. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47 (1): 153-205.
21. Erard V, Wald A, Corey L, Leisenring WM, Boeckh M. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation: impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007; 196 (2): 266-270.
22. Chakrabarti S, Pillay D, Ratcliffe D, Cane PA, Collingham KE, Milligan DW. Resistance to antiviral drugs in herpes simplex virus infections among allogeneic stem cell transplant recipients: risk factors and prognostic significance. J Infect Dis 2000; 181 (6): 2055-2058.
23. Chen Y, Scieux C, Garrait V, et al. Resistant herpes simplex virus type 1 infection: an emerging concern after allogeneic stem cell transplantation. Clin Infect Dis 2000; 31 (4): 927-935.
24. Langston AA, Redei I, Caliendo AM, et al. Development of drug-resistant herpes simplex virus infection after haploidentical hematopoietic progenitor cell transplantation. Blood 2002; 99 (3): 1085-1088.
25. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26 (1): 29-37.